Stocklytics Platform
Asset logo for symbol TVTX
Travere Therapeutics
TVTX55
$17.07arrow_drop_down8.06%-$1.50
High Growth
Asset logo for symbol TVTX
TVTX55

$17.07

arrow_drop_down8.06%

Analyst Forecast

Period: Next 12 Months

•

Analyst Ratings

•
•

Travere Therapeutics (TVTX) Stocklytics Forecast

Travere Therapeutics, Inc. (TVTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies for patients with rare diseases. The company has a diverse pipeline of product candidates targeting a variety of rare genetic disorders. With its strong research and development capabilities, Travere Therapeutics is poised to make significant advancements in the treatment of these diseases.
When it comes to predicting the stock price of Travere Therapeutics, Inc. (TVTX), there are several factors to consider. While past performance is not always indicative of future results, it is useful to analyze historical data and trends. Additionally, market conditions, industry developments, and company-specific news can also impact the stock price. It is important for investors to conduct thorough research and analysis before making any investment decisions.
add Travere Therapeutics to watchlist

Keep an eye on Travere Therapeutics

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
help

What is the analyst price prediction for Travere Therapeutics (TVTX) stock?

Analysts have set a target price of $20.48 for Travere Therapeutics (TVTX), based on forecasts from 27 analysts. The predicted price range extends from a high of $39 to a low of $7. This represents a potential increase of up to 128.47% and a decrease of -58.99% from the current price of $17.07. These forecasts are as of 2023 Apr 17.
help

What are the analyst ratings for Travere Therapeutics (TVTX) stock?

The analyst ratings for Travere Therapeutics (TVTX) are distributed as follows: 13 analysts recommend buying, 2 have a neutral stance, and 0 suggest selling. The prevailing sentiment among the total of 15 analysts leans towards a buy rating. These ratings indicate the general sentiment among the analysts covering Travere Therapeutics.
help

What is the AI price prediction for Travere Therapeutics (TVTX) stock?

At present, there is no AI or machine-learning-based price prediction available for Travere Therapeutics (TVTX) stock. The lack of a forecast could stem from various factors, such as inadequate data or the necessity for model recalibration.

Take Your Investments to a Whole New Level